Nigam Mishra

Nigam Mishra

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2015 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
NMNigam Mishra
Nigam Mishra
YBYves Briers
Yves Briers
CLChris Lamberigts
Chris Lamberigts
HSHans Steenackers
Hans Steenackers
SRStijn Robijns
Stijn Robijns
EEErik Van Der Eycken
Erik Van Der Eycken
We report the design, synthesis and antibacterial activity analysis of conjugates of vancomycin and cathelicidin-related antimicrobial peptides (CRAMP). Vancomycin inhibits the nascent peptidoglycan synthesis and is highly active against Gram-positive bacteria, whereas Gram-negative bacteria are generally insensitive due to a protective outer membrane. CRAMP is known to translocate across the Gram-negative outer membrane by a self-promoted uptake mechanism. Vancomycin–CRAMP conjugates were synthesized using click chemistry with diverse hydrophilic and hydrophobic linkers, with CRAMP functioning as a carrier peptide for the transfer of vancomycin through the outer membrane. Small hydrophobic linkers with an aromatic group result in the most active conjugates against planktonic Gram-negative bacteria, while maintaining the high activity of vancomycin against Gram-positive bacteria. These conjugates thus show a broad-spectrum activity, which is absent in CRAMP or vancomycin alone, and which is strongly improved compared to an equimolar mixture of CRAMP and vancomycin. In addition, these conjugates also show a strong inhibitory activity against S. Typhimurium biofilm formation.


1 December 2017 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
FVFrancesca Vallese
Francesca Vallese
NMNigam Mishra
Nigam Mishra
MPMatteo Pagliari
Matteo Pagliari
PBPaola Berto
Paola Berto
Gaia CodoloGaia Codolo
Gaia Codolo
Giuseppe ZanottiGiuseppe Zanotti
Giuseppe Zanotti

7 June 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
NMNigam Mishra
Nigam Mishra
ISIzabela Stolarzewicz
Izabela Stolarzewicz
DCDavid Cannaerts
David Cannaerts
JSJoris Schuermans
Joris Schuermans
RLRob Lavigne
Rob Lavigne
YBYves Briers
Yves Briers
Vancomycin is a glycopeptide antibiotic that inhibits transpeptidation during cell wall synthesis by binding to the D-Ala-D-Ala termini of lipid II. For long, it has been used as a last resort antibiotic. However, since the emergence of the first vancomycin-resistant enterococci in 1987, vancomycin resistance has become widespread, especially in hospitals. We have synthesized and evaluated 110 vancomycin analogs modified at the C-terminal carboxyl group of the heptapeptide moiety with R2NHR1NH2 substituents. Through iterative optimizations of the substituents, we identified vancomycin analogs that fully restore (or even exceed) the original inhibitory activity against vancomycin-resistant enterococci (VRE), vancomycin-intermediate (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) strains. The best analogs have improved growth inhibitory activity and in vitro therapeutic indices against a broad set of VRE and methicillin-resistant S. aureus (MRSA) isolates. They also exceed the activity of vancomycin against Clostridium difficile ribotypes. Vanc-39 and Vanc-42 have a low probability to provoke antibiotic resistance, and overcome different vancomycin resistance mechanisms (VanA, VanB, and VanC1).

11 December 2012 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
NMNigam Mishra
Nigam Mishra
DVDipak D. Vachhani
Dipak D. Vachhani
SMSachin G. Modha
Sachin G. Modha
EEErik Van Der Eycken
Erik Van Der Eycken

29 September 2022 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AQAlshaima'A M. Qunies
Alshaima'A M. Qunies
NMNigam Mishra
Nigam Mishra
BSBrittany D. Spitznagel
Brittany D. Spitznagel
YDYu Du
Yu Du
VAValerie S. Acuña
Valerie S. Acuña
Kyle A. EmmitteKyle A. Emmitte
Kyle A. Emmitte